

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 9/127, 7/00	A1	(11) International Publication Number: WO 91/12794 (43) International Publication Date: 5 September 1991 (05.09.91)
(21) International Application Number: PCT/EP91/00267 (22) International Filing Date: 11 February 1991 (11.02.91) (30) Priority data: P 40 05 711.9 23 February 1990 (23.02.90) DE (71) Applicant (for all designated States except US): NATTERMANN, A. & CIE. GMBH [DE/DE]; Nattermannallee 1, D-5000 Köln 30 (DE). (72) Inventors; and (75) Inventors/Applicants (for US only) : LAUTENSCHLÄGER, Hans, Heiner [DE/DE]; Neusser Gasse 50, D-5024 Pulheim 3 (DE). RÖDING, Joachim [DE/DE]; Weißenburgerstr. 33, D-5000 Köln 1 (DE). GHYCZY, Miklos [DE/DE]; Im Rapsfeld 23, D-5000 Köln 41 (DE).		(74) Agents: STERNAGEL, Hans-Günther et al.; Sander Aue 30, D-5060 Bergisch Gladbach 2 (DE). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: AQUEOUS PHOSPHOLIPID VESICLE DISPERSION, PROCESS FOR ITS MANUFACTURE AND USE THEREOF (57) Abstract Aqueous phospholipid dispersion, whose membranes are formed from a mixture of phosphatidylcholine and a specific phospholipid basic substance, provide a particularly favourable loading of the vesicle membrane with lipophilic substances. The vesicle dispersions prepared according to a particular method can be used for pharmaceutical and cosmetic compositions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TC	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

- 1 -

Title: Aqueous phospholipid vesicle dispersion.
 process for its manufacture and use thereof

Description

The subject of the invention is an aqueous dispersion of phospholipid vesicles, a process for its manufacture and its use in pharmaceutical or cosmetic preparations.

Liposomes are vesicles and can possess structures of very different types. Depending on the method of preparation it is possible to distinguish unilamellar, oligolamellar, multilamellar or fused bodies with a membrane structure and a diameter of about 15 to 3500 nm.

In generally accepted speech liposomes are prepared from natural, semisynthetic or synthetic phospholipids, whereby the principal component is usually phosphatidylcholine. Other components are typically phosphatidylethanolamine, phosphatidylinositol and phosphatidic acid. A distinction is made between unsaturated (natural), partially hydrogenated and hydrogenated phospholipids according to their fatty acid composition. The subject is reviewed in H.P. Fiedler, Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete, Verlag Editio Cantor, Aulendorf 1989, pp 744-746.

In their article Lautenschläger et al. have emphasized the importance of liposomes from soy phospholipids in cosmetics (Seifen-Öle-Fette-Wachse 114 (1988), 531-534), while Skoza and Papahadjopoulos have provided a detailed description of

the preparation of specific phospholipid vesicles (Ann. Rev. Biophys. Bioeng. 1980, 9, 467-476).

However, the present invention is not suggested even by a combination of the above mentioned publications.

In a manner similar to biological cells liposomes can take up water-soluble substances in the internal vesicular volumes and amphiphilic and lipophilic substances in the membranes (loaded liposomes). Experience has shown that loading of the membranes is of more interest for the application of liposomes in cosmetics and pharmaceuticals than loading of the internal vesicular volume, since in the former case the loaded substance remains largely associated with the membranes when the liposomes are mixed with other components of the formulation. In the case of water-soluble substances which are located in the internal volumes of the liposomes it must be expected that even the addition of water will bring about losses - particularly in the case of low molecular weight substances.

The liposomes available until now have significant disadvantages in spite of the properties mentioned above:

1. On account of the high purity materials usually employed - primarily highly refined phosphatidylcholines - and the complicated method of preparation used liposomes of classical composition are appreciably more expensive than normal emulsions with less favourable properties.
2. Liposomes of classical composition only possess a limited storage capacity for lipophilic substances. Liposomes formed from unsaturated phospholipids may be able to incorporate ca. 10 to 30% of their weight of triglycerides, but even for a highly concentrated liposome dispersion containing 10%

liposome component (in the dry substance) this still means a final concentration of only 1 to 3% triglyceride in the complete formulation. In contrast 10 to 20% lipophilic component concentrations are normal for comparable oil-in-water emulsions.

The object of this invention is, therefore, to provide an aqueous dispersion of vesicles whose phospholipid membrane walls are particularly suitable for loading with lipophilic substances.

This object is achieved by an aqueous vesicle dispersion comprising phospholipid vesicles, water and, if necessary, inorganic and/or organic electrolytes characterized in that the membranes of the vesicles consist of a mixture of 10 to 40 parts by weight phosphatidylcholine, 30 to 80 parts by weight of a lipophilic substance and 10 to 30 parts by weight of a phospholipid base substance and that this has the following composition:

15 to 25% by weight phosphatidylethanolamine,
15 to 25% by weight phosphatidylinositol,
15 to 25% by weight phosphatidic acid,
15 to 0% by weight phosphatidylcholine,
0 to 1% by weight oil,
40 to 24% by weight accompanying substances normally found
in lecithin,

where the sum of the total amounts is 100% and the vesicle dispersion comprises 35.0 to 99.7% by weight water as a proportion of the total weight.

To this dispersion can also be added 0.1 to 5% by weight of an inorganic base and/or organic base and 0.1 to 5% by weight of an inorganic and/or organic electrolyte in order

to adjust the complete mixture to a physiological pH and a physiological osmolarity.

For good physiological compatibility the pH value is adjusted to the 5 to 8 range, preferably between 6.5 and 7. The osmolarity range is 150 to 450 m osmol/L and preferably 250 to 350 m osmol/L.

Lipophilic substances are particularly well retained by the vesicle membranes. Thus the membranes can be loaded with vitamin E, retinoids, steroids, lipophilic and amphiphilic active substances, vegetable and animal oils, radical scavengers and UV absorbers. Oils are particularly favoured lipophilic substances.

In particular lipophilic active substances, vegetable and animal oils are important for optimal skin care in the cosmetic field, especially for the treatment of dry skin. In the case of polyunsaturated oils, such as are used for the treatment of atopic dermatitis (H.P. Nissen, W. Wehrmann, U. Kroll and H.W. Kreysel, *Fat. Sci. Technol.* 90 (7), 268-271 (1988)), the distribution and penetration of the skin is of decisive importance. For this reason liposomes are the ideal carrier system for distribution and penetration of the skin.

The greater loading of the phospholipid membrane walls also tends to favour the uptake of greater concentrations of triglycerides.

The substantial loading of the membranes makes it possible to employ the vesicle dispersions according to the invention for pharmaceutical and cosmetic formulations. These can not only incorporate active ingredients but also the additives commonly employed in such compositions.

- 5 -

According to the invention the vesicle dispersion comprising aqueous phospholipid vesicles, water and any inorganic and/or organic electrolytes is prepared by dispersing the phospholipids in water. The procedure is as follows: 0.1 to 20 parts by weight of a phospholipid base of the following composition:

15 to 25% by weight phosphatidylethanolamine,
15 to 25% by weight phosphatidylinositol,
15 to 25% by weight phosphatidic acid,
15 to 0% by weight phosphatidylcholine,
0 to 1% by weight oil,
40 to 24% by weight accompanying substances normally found
in lecithin

is dispersed in 99.7 to 35 parts by weight water at a temperature between 10°C and 80°C, 0.1 to 20 parts by weight phosphatidylcholine are incorporated, 0.1 to 25 parts by weight of a lipophilic substance are added and, if necessary, the pH value of the dispersion is adjusted to a value between 5 and 8 by the addition of inorganic or organic base, if necessary, the dispersion is adjusted to the desired osmolarity by the addition of an inorganic and/or organic electrolyte and then further homogenized whereby the total time of homogenization is 5 to 60 minutes.

In the method according to the invention the phosphatidylcholine can be added as the pure substance, in the form of an oil-containing fraction or in a component that also contains oil-containing or lipophilic materials.

The basic substance consists of a phospholipid mixture containing a particularly high proportion of accompanying phospholipids (with respect to phosphatidylcholine) and which can have the following composition:

- 6 -

15 to 25% by weight phosphatidylethanolamine,
15 to 25% by weight phosphatidylinositol,
15 to 25% by weight phosphatidic acid,
15 to 0% by weight phosphatidylcholine,
0 to 1% by weight oil,
40 to 24% by weight accompanying substances normally
found in lecithin,

whereby the total sum amounts to 100% by weight for each composition.

The basic substance is a granulatable solid of colourless to pale beige appearance manufactured by the extraction of raw lecithin with ethanol after which the extraction residue is subjected to the deoiling process usual for raw lecithin (cf. H. Pardun, Die Pflanzenlecithine, Verlag für chemische Industrie, Augsburg 1988) and hence is very economically priced.

On account of the "natural starting material" the composition of the basic substance is subject to variations which can affect the pH and osmolarity of the dispersions produced. It is, therefore, appropriate to adjust the pH range of the dispersion being optimal for phospholipids to between 6 and 7, preferably 6.5 with a base, for example sodium hydroxide, potassium hydroxide, lithium hydroxide, triethanolamine etc., such as is usually employed in pharmacy or cosmetics and then to adjust to the desired physiological osmolarity in the range of 150 to 450 and preferably 250 to 350 m osmol/L by adding a suitable electrolyte. The preferred electrolytes are alkali metal salts such as sodium chloride, sodium sulphate and other sulphates, chlorides and phosphates. The dispersion can also be brought to the desired osmolarity with the aid of a conventional citrate or phosphate buffer.

Naturally other ionic additives that promote the purpose for which the formulation is intended and that are compatible with the formulation can also be used. Particularly in the manufacture of cosmetic preparations, for instance, salts of lactic acid and of pyrrolidone carboxylic acid can be incorporated as components of the natural moisturizing factor.

The temperature of preparation of the dispersion has little effect on the physical properties of the formulation. It is, therefore, convenient to work at room temperature or in the temperature range of 10 to 80°C. This means that temperatures in the range of 70 to 80°C, usual for the reduction of microbial contamination, can be employed. If desired the system can also be processed at lower or higher temperatures.

The process also possesses the additional great advantage that there is no need to add any of the conventional additives for vesicle preparation, e.g., cholesterol, glycerol, dicetyl phosphate, and only physiologically compatible components are required.

The proportions of basic substance, of phosphatidylcholine and oil (or of any other cosmetically, pharmaceutically or technically interesting lipophilic substance) can be varied within the following limits:

Basic substance	0.1 to 20.0%
Phosphatidylcholine	0.0 to 20.0%
Lipophilic substance, e.g., oil	0.0 to 25.0%

It is evident from these figures that the basic substance alone can produce vesicles and can be combined with lipophilic substances without the addition of phosphatidylcholine. On the other hand given proportions of basic substance and phosphatidylcholine correspond to a maximum amount of

lipophilic substance (oil), of which as high a proportion as possible is the aim of this invention. Furthermore it has been found that it is not absolutely necessary to add phosphatidylcholine as the pure substance since it can be added in the form of "fractions" i.e., in enriched form too. Such "fractions" are commercially available and contain large proportions of oil (25 to 75%). This oil component is usually soy, sunflower, thistle or rape oil. On the other hand "compounds" of phosphatidylcholine and oils or "fractions" and oils are also applied since they are easier to handle.

The cosmetic formulations so produced combine the excellent skin-care properties of the phospholipids (lecithins) and of the native oils or other lipophilic agents conventionally used in cosmetics with simultaneous excellent distribution and skin penetration (H. Lautenschläger, J. Rödiger and M. Ghyczy, Seifen, Öle, Fette, Wachse 114 (14), 531 (1988)). Thus the preparations described can be employed successfully for daily facial and body care, particularly for the treatment of dry skin, for the treatment of skin blemishes and for the re-establishment of optimal linoleic acid levels in the deeper layers of the skin.

The basic substance employed in the examples had the following composition
(Source: soybeans):

Phosphatidylethanolamine,	20.2% by weight
Phosphatidylinositol,	19.4% by weight
Phosphatidic acid,	22.0% by weight
Phosphatidylcholine,	10.6% by weight
N-acylcephalin	2.3% by weight
Lysolecithin	less than 1.0% by weight
Oil	less than 1.0% by weight

Other substances normally accompanying
lecithin to 100.0% by weight

Example 1

A mixture of 5 g basic substance and 7 g phosphatidylcholine (Phospholipon 90[®]) is homogenized in 62.14 g water with the aid of a high performance stirrer (e.g., rotor-stator based, dissolver-stirrer or high pressure homogenizer). Then 20 g soybean oil is stirred into the dispersion, the mixture is homogenized once more and then adjusted to physiological osmotic pressure by the addition of 0.73 g sodium chloride and 5 g water with further homogenization. The dispersion is filtered and can - if desired - be treated with a preservative to improve storage.

The mean particle size of the vesicles so formed is 420 nm (measured by the laser scattering method).

This example indicates that it is possible to achieve an oil content of ca. 20% in the complete formulation even with a relatively small proportion of phosphatidylcholine. The oil concentration is six times higher than that of classical liposome concentrates, even though the phosphatidylcholine content is only ca. one half that usually employed.

The dispersion can be prepared using practically all types of stirrers conventionally employed in the manufacture of pharmaceuticals and cosmetics. The vesicles produced are larger or smaller depending on the stirrer employed and the stirring time, which may vary between 5 and 60 minutes. In general the vesicle size lies in the range of 100 to 500 nm but can also lie below 100 nm.

Example 2

A mixture of 5 g basic substance and 5 g phosphatidylcholine (Phospholipon 90^R) is homogeneously dispersed in 80 g water with the aid of a high performance stirrer. The dispersion is then neutralized (pH 7) with a little sodium hydroxide, 15 g evening primrose oil is stirred in and the mixture homogenized once more, its osmolarity is then adjusted to physiological osmolarity with sodium citrate while it is further homogenized. The dispersion is filtered and can - if desired - be treated with a suitable preservative to improve storage.

The mean particle size is 210 nm
(laser scattering method).

Example 3

A dispersion of 5 g basic substance in 80 g water is prepared by homogenizing with a high efficiency stirrer. Into the dispersion is stirred 15 g of a "compound" of 50% phosphatidylcholine and 50% oil (major component thistle oil; commercial name: Phosal 50 SA^R), the mixture is adjusted to pH 6.5 to 7 with a little sodium hydroxide, homogenized again and finally adjusted to a physiological osmolarity by the addition of a little sodium chloride under continued homogenization. The dispersion is filtered and can - if desired - be treated with a suitable preservative to improve storage.

The mean particle size is 251 nm
(laser scattering method).

Naturally in the method described in Example 3 the "compound" can be diluted with thistle oil, other oils or lipophilic cosmetic or pharmaceutical active ingredients before addition to the basic substance dispersion so as to achieve

other desired oil or active ingredient concentrations. The dispersions so prepared can be used directly for the manufacture of pharmaceutical, cosmetic and technical products as illustrated in the following example of a cosmetic skin care formulation.

Example 4

A 100 g sample of the dispersion obtained in Example 1 is placed in vacuum and treated with 0.5 g xanthan gum (Rhodigel 200[®]) with vigorous stirring, when the viscosity is greatly increased and further stirring yields the completed skin care product.

Naturally in the case of the process described in Example 4 all the usual compatible cosmetic additives and active ingredients such as antioxidants, preservatives, gel formers, consistency providers, perfumes, vitamins etc. can be added to and worked into the product according to the methods known to the expert in the art.

Example 5 illustrates the typical preparation of a liposome creme:

Example 5

A high performance stirrer is employed to disperse 5 g basic substance homogeneously in 64.6 g water. Homogenization is continued while 7 g phosphatidylcholine (Phospholipon 90[®]), 10 g jojoba oil (Dragoco) and 0.2 g vitamin E acetate (Rhône-Poulenc) are added in succession. The dispersion is buffered with a mixture of 0.7 g potassium dihydrogen phosphate, 0.9 g disodium hydrogen phosphate dodecahydrate ($\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$) and 5 g water and briefly homogenized once again; this adjusts the pH to 6.5. The vesicle size is 493 nm,

- 12 -

the osmolarity 267 m osmol. Then a solution of 5 g propylene glycol and 0.5 g phenonip (NIPA) is added as preservative, 1 g xanthan gum (Rhodigel 200[®]) is added as thickening agent and 0.1 g perfume oil as perfume agent. Finally the complete mixture is homogenized once more and the product is filled into tubes.

Claims:

1. Aqueous vesicle dispersion comprising phospholipid vesicles, water and, if necessary, inorganic and/or organic electrolytes, characterized in that the membranes of the vesicle consist of 10 to 30% by weight of a mixture of a phospholipid base substance with the following composition:

15 to 25% by weight phosphatidylethanolamine,
15 to 25% by weight phosphatidylinositol,
15 to 25% by weight phosphatidic acid,
15 to 0% by weight phosphatidylcholine,
0 to 1% by weight oil,
40 to 24% by weight accompanying substances normally found
in lecithin,

where the sum of the total amounts is 100% by weight in each case,

10 to 40% by weight phosphatidylcholine and
30 to 80% by weight of a lipophilic substance
and the vesicle dispersion contains 35.0 to 99.7% by weight water as proportion of the total weight.

2. Aqueous dispersion according to Claim 1 characterized in that the vesicle dispersion contains

0.1 to 5% by weight of an inorganic and/or organic base
and/or

0.1 to 5% by weight of an inorganic and/or organic electrolyte.

3. Aqueous vesicle dispersion according to Claim 1 characterized in that the lipophilic substance is an oil.

4. Method for the preparation of an aqueous vesicle dispersion according to any of Claims 1 to 3, by dispersing the vesicle-forming substance in water characterized by dispersing 0.1 to 20 parts by weight of a phospholipid basic substance of the following composition:

15 to 25% by weight phosphatidylethanolamine,
15 to 25% by weight phosphatidylinositol,
15 to 25% by weight phosphatidic acid,
15 to 0% by weight phosphatidylcholine,
0 to 1% by weight oil,
40 to 24% by weight accompanying substances normally found in lecithin,

at a temperature between 10°C and 80°C in 99.7 to 35 parts by weight water, with the addition of 0.1 to 20 parts by weight phosphatidylcholine, the incorporation of 0.1 to 25 parts by weight of a lipophilic substance, if necessary the adjustment of the pH of the dispersion with an inorganic or organic base to a value between 5 and 8 and if necessary adjustment of the desired osmolarity by addition of an inorganic and/or organic electrolyte followed by homogenization by stirring with a total homogenization time of 5 to 60 minutes.

5. A method for the preparation of a vesicle dispersion according to Claim 4 characterized in that the phosphatidylcholine is added as pure substance, in the form of an oil-containing fraction or as a component with oil-containing or lipophilic substances in addition to phosphatidylcholine.
6. Use of the aqueous vesicle dispersion according to any of Claims 1 to 5 in pharmaceutical or cosmetic compositions characterized in that additives are added to these compositions, if necessary.

7. Use according to Claim 6 for the manufacture of cosmetic compositions for skin care.

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 91/00267

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 9/127, A 61 K 7/00																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC⁵</td> <td style="padding: 5px;">A 61 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	A 61 K											
Classification System	Classification Symbols																
IPC ⁵	A 61 K																
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁹</th> <th style="border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 10%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">FR, A, 2455458 (KUREHA KAGAKU KOGYO K.K.) 28 November 1980 see page 6, line 1 - page 7, line 16; page 16, table 2, examples 2-6; claims ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,3</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">EP, A, 0095591 (A. NATTERMANN & CIE GmbH) 7 December 1983 see page 6, example 7; page 7, example 10 ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-7</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;">EP, A, 0299937 (LARSSON) 18 January 1989 see column 3, line 1 - column 5, line 16; column 7, example 5; claims 1-6 ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-7</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">EP, A, 0088046 (CIBA-GEIGY AG) 7 September 1983 see page 25, example 4 ---</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	Y	FR, A, 2455458 (KUREHA KAGAKU KOGYO K.K.) 28 November 1980 see page 6, line 1 - page 7, line 16; page 16, table 2, examples 2-6; claims ---	1,3	Y	EP, A, 0095591 (A. NATTERMANN & CIE GmbH) 7 December 1983 see page 6, example 7; page 7, example 10 ---	1-7	Y	EP, A, 0299937 (LARSSON) 18 January 1989 see column 3, line 1 - column 5, line 16; column 7, example 5; claims 1-6 ---	1-7	A	EP, A, 0088046 (CIBA-GEIGY AG) 7 September 1983 see page 25, example 4 ---	1
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
Y	FR, A, 2455458 (KUREHA KAGAKU KOGYO K.K.) 28 November 1980 see page 6, line 1 - page 7, line 16; page 16, table 2, examples 2-6; claims ---	1,3															
Y	EP, A, 0095591 (A. NATTERMANN & CIE GmbH) 7 December 1983 see page 6, example 7; page 7, example 10 ---	1-7															
Y	EP, A, 0299937 (LARSSON) 18 January 1989 see column 3, line 1 - column 5, line 16; column 7, example 5; claims 1-6 ---	1-7															
A	EP, A, 0088046 (CIBA-GEIGY AG) 7 September 1983 see page 25, example 4 ---	1															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center; padding: 5px;">21st May 1991</td> <td style="text-align: center; padding: 5px;">30.07.91</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; padding: 5px;">EUROPEAN PATENT OFFICE</td> <td style="text-align: center; padding: 5px;">F.W. HECK </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	21st May 1991	30.07.91	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	F.W. HECK							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
21st May 1991	30.07.91																
International Searching Authority	Signature of Authorized Officer																
EUROPEAN PATENT OFFICE	F.W. HECK																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	SOFW, volume 115, no. 18, 21 November 1989, (Augsburg, DE), H. Lautenschläger: "Kosmetische Formulierungen mit Liposomen und Phospholipiden-Umfeld und Zusammenhänge", pages 662-663 see page 663 ---	7
P,Y	WO, A, 9012565 (NATTERMANN & CIE GmbH) 1 November 1990 see pages 18,19, examples 15-17 -----	1-7

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9100267
SA 44444

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 28/06/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 2455458	28-11-80	JP-B- 2040644	12-09-90
		JP-A- 55153713	29-11-80
		CA-A- 1143656	29-03-83
		DE-A- 3016976	13-11-80
		GB-A, B 2050287	07-01-81
EP-A- 0095591	07-12-83	DE-A- 3218027	17-11-83
		JP-A- 58206597	01-12-83
		US-A- 4482474	13-11-84
EP-A- 0299937	18-01-89	SE-C- 457933	08-06-89
		JP-A- 1061421	08-03-89
		SE-B- 8457933	13-02-89
EP-A- 0088046	07-09-83	AU-B- 558810	12-02-87
		AU-A- 1149083	25-08-83
		CA-A- 1219215	17-03-87
		DE-A- 3374837	21-01-88
		US-A- 4619794	28-10-86
		JP-A- 58152812	10-09-83
WO-A- 9012565	01-11-90	None	

EPO FORM 1009

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82